Revenues of Cartesian Therapeutics, Inc. from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Cartesian Therapeutics, Inc. quarterly and annual Revenues in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • Cartesian Therapeutics, Inc. Revenues for the quarter ending 31 Dec 2025 was $947,000.
  • Cartesian Therapeutics, Inc. Revenues for the twelve months ending 31 Dec 2025 was $2,797,000, a 93% decline year-over-year.
  • Cartesian Therapeutics, Inc. annual Revenues for 2025 was $2,797,000, a 93% decline from 2024.
  • Cartesian Therapeutics, Inc. annual Revenues for 2024 was $38,913,000, a 50% increase from 2023.
  • Cartesian Therapeutics, Inc. annual Revenues for 2023 was $26,004,000.
Source SEC data
View on sec.gov
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Change (%)
Revenues, Annual (USD)
Revenues, YoY Annual Change (%)

Cartesian Therapeutics, Inc. Quarterly Revenues (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $2,797,000 $947,000 +$1,706,000 01 Oct 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 $1,091,000 $452,000 +$65,000 +17% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $1,026,000 $298,000 -$33,147,000 -99% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $34,173,000 $1,100,000 -$4,740,000 -81% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $38,913,000 $759,000 01 Oct 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 $387,000 -$6,164,000 -94% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $33,445,000 +$28,196,000 +537% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $5,840,000 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q3 2023 $6,551,000 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $5,249,000 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2018 $70,000 $0 -$137,000 -100% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2018 2018 Q1
Q4 2017 $207,000 $17,000 -$2,913,000 -99% 01 Oct 2017 31 Dec 2017 10-K 15 Mar 2018 2017 Q4
Q3 2017 $3,120,000 $27,000 -$1,021,000 -97% 01 Jul 2017 30 Sep 2017 10-K 15 Mar 2018 2017 Q4
Q2 2017 $4,141,000 $26,000 -$1,991,000 -99% 01 Apr 2017 30 Jun 2017 10-K 15 Mar 2018 2017 Q4
Q1 2017 $6,132,000 $137,000 -$1,951,000 -93% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $8,083,000 $2,930,000 +$796,000 +37% 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2018 2017 Q4
Q3 2016 $7,287,000 $1,048,000 -$559,000 -35% 01 Jul 2016 30 Sep 2016 10-K 15 Mar 2018 2017 Q4
Q2 2016 $7,846,000 $2,017,000 +$781,000 +63% 01 Apr 2016 30 Jun 2016 10-K 15 Mar 2018 2017 Q4
Q1 2016 $7,065,000 $2,088,000 +$1,054,000 +102% 01 Jan 2016 31 Mar 2016 10-K 15 Mar 2018 2017 Q4
Q4 2015 $6,011,000 $2,134,000 01 Oct 2015 31 Dec 2015 10-K 28 Mar 2017 2016 FY
Q3 2015 $1,607,000 01 Jul 2015 30 Sep 2015 10-K 28 Mar 2017 2016 FY
Q2 2015 $1,236,000 01 Apr 2015 30 Jun 2015 10-K 28 Mar 2017 2016 FY
Q1 2015 $1,034,000 01 Jan 2015 31 Mar 2015 10-K 28 Mar 2017 2016 FY

Cartesian Therapeutics, Inc. Annual Revenues (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $2,797,000 -$36,116,000 -93% 01 Jan 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
2024 $38,913,000 +$12,909,000 +50% 01 Jan 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
2023 $26,004,000 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2017 $207,000 -$7,876,000 -97% 01 Jan 2017 31 Dec 2017 10-K 15 Mar 2018 2017 Q4
2016 $8,083,000 +$2,072,000 +34% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2018 2017 Q4
2015 $6,011,000 +$2,971,000 +98% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2018 2017 Q4
2014 $3,040,000 01 Jan 2014 31 Dec 2014 10-K 28 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.